- Category: News
- Published on Thursday, 23 February 2012 19:05
- Written by Lara Landis
- Hits: 471
Biosante’s Libigel may or may not be approved by the FDA. Even though the outlook looks bleak for the testosterone gel, drug makers have not given up on their attempt to produce a ‘female Viagra’.
S1 Pharmaceuticals, Incorporated submitted an investigative new drug application to the Food and Drug Administration. The proposed new drug, Lorexys, works on the central nervous system. Researchers hope that the drug will work with the central nervous system to improve the symptoms of HSDD and Female Sexual Dysfunction.
HSDD, a controversial disorder, will remain in the next edition of the DSM. Women can be diagnosed with a similar equivalent.
Lorexys will need to go through many safety trials before the FDA makes its final decision. Pharmaceutical companies must collect safety information before moving to Phase II trials.